This presentation provides an insightful exploration of GSK's innovative journey in integrating Large Language Models (LLMs) into biostatistics. It begins with the strategic introduction of LLMs to users, progressing through to the pioneering LLM …
This presentation provides an insightful exploration of GSK's innovative journey in integrating Large Language Models (LLMs) into biostatistics. It begins with the strategic introduction of LLMs to users, progressing through to the pioneering LLM …
Over the past few decades, the volume of data available to support drug and biological product development have increased substantially. These increases in data volume were also accompanied by an expansion in data diversity with data originating from …
Over the past few decades, the volume of data available to support drug and biological product development have increased substantially. These increases in data volume were also accompanied by an expansion in data diversity with data originating from …
R users tend to be skeptical of modern AI models, given our weird insistence on answers being accurate, or at least supported by the data. But I believe the time has come—or maybe it’s a little late—for even the most AI-cynical among us to push past …
R users tend to be skeptical of modern AI models, given our weird insistence on answers being accurate, or at least supported by the data. But I believe the time has come—or maybe it’s a little late—for even the most AI-cynical among us to push past …
Programming is ubiquitous in applied biostatistics, and most statisticians know a programming language such as R - yet software engineering is still neglected as a skill and undervalued as a profession in pharmaceutical statistics. Why is this a …
Historically building a great SCE for clinical reporting involved selecting a vendor, integrating their product, and supporting a single proprietary language. The shift to report clinical trials using R has had a much broader impact than just …
Data sources and the volume of data available for driving discovery and informing decisions have substantially increased over time. This increase has resulted in an evolving data and regulatory landscape ripe for the expertise of statisticians and …
I will talk about some of the challenges that are now arising in BioTech. There are larger, more informative but much more complex, data sets available and being developed. While these hold great promise they add complexity to an already fragile …